FY2025 EPS Estimate for Connect Biopharma Lowered by Analyst

Key Points

• Northland Capmk has lowered its FY2025 earnings forecast for Connect Biopharma to ($0.92) per share, compared to a previous estimate of ($0.90).
• HC Wainwright maintains a "buy" rating for the stock with a price target of $7.00, while the consensus rating is "Strong Buy."
• Connect Biopharma's stock is currently trading at $1.56, having a significant trading range between a 12-month low of $0.51 and a high of $2.86.

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Equities researchers at Northland Capmk cut their FY2025 EPS estimates for shares of Connect Biopharma in a research note issued to investors on Thursday, September 11th. Northland Capmk analyst C. Byrnes now forecasts that the company will earn ($0.92) per share for the year, down from their prior forecast of ($0.90). Northland Capmk currently has a "Strong-Buy" rating on the stock. The consensus estimate for Connect Biopharma's current full-year earnings is ($0.22) per share.

Several other analysts also recently issued reports on the stock. Wall Street Zen raised shares of Connect Biopharma to a "hold" rating in a report on Friday, August 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price target on shares of Connect Biopharma in a research note on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Strong Buy" and a consensus price target of $7.00.

Connect Biopharma Stock Performance

CNTB stock traded down $0.04 on Monday, hitting $1.57. 19,948 shares of the company's stock traded hands, compared to its average volume of 135,004. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.01. Connect Biopharma has a 1-year low of $0.51 and a 1-year high of $2.86. The stock has a fifty day moving average of $1.90 and a 200-day moving average of $1.20.

Institutional Trading of Connect Biopharma

Hedge funds have recently bought and sold shares of the company. XTX Topco Ltd bought a new position in shares of Connect Biopharma during the second quarter valued at approximately $29,000. Koa Wealth Management LLC bought a new stake in shares of Connect Biopharma in the second quarter worth $49,000. Finally, AlphaCore Capital LLC purchased a new position in Connect Biopharma during the second quarter valued at $78,000. Institutional investors own 58.72% of the company's stock.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.